查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552861

法布瑞氏症治疗市场规模、份额和趋势分析报告：按解决方案、治疗方法、给药途径、分销管道、地区和细分市场预测，2024-2030年

Fabry Disease Treatment Market Size, Share & Trends Analysis Report By Solution, By Treatment (Enzyme Replacement Therapy), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

法布瑞氏症治疗市场成长与趋势

Grand View Research, Inc.最新报告显示，预计到2030年，全球法布瑞氏症治疗市场规模将达到49.3亿美元，2024年至2030年复合年增长率为9.9%。

接受法布瑞氏症治疗的患者数量不断增加，Chaperone疗法等新型治疗方法的采用越来越多，以及基材减少疗法和酵素替代疗法等管道药物的潜在核准，都为市场提供了动力。

法布瑞氏症治疗是一种罕见的遗传性溶小体贮积症，由抑制 α-半乳糖苷酶功能的基因突变所引起。法布瑞氏症的治疗通常症状轻微且起病缓慢，因此许多患者常常未被诊断出来。法布瑞氏症的标准治疗方法是酵素替代疗法（ERT）。赛诺菲的 Fabrazyme 和 Shire 的 Repregal 是唯一在欧盟核准的ERT，而 Fabrazyme 是唯一在美国核准的ERT。

目前临床试验的重点是提高 ERT 的安全性和有效性，并引入新型口服疗法，以消除静脉注射的需要。最近，Amicus Therapeutics 的 Galafold 在美国、加拿大、欧盟、日本、澳洲、以色列和韩国被核准为首个成人的口服Chaperone疗法。

2017年，北美占据法布瑞氏症治疗市场最大份额，其次是欧洲。该地区的成长得益于新治疗方法的高采用率、有利的报销政策和改善的医疗设施。然而，Fabrazyme 等 ERT 治疗的高成本在新兴市场中构成了阻碍因素。

法布瑞氏症治疗市场报告亮点

  • 静脉注射在 2023 年占据市场主导地位，市场占有率为 65.9%，预计在 2024-2030 年预测期内将以最快的复合年增长率成长。
  • 酵素替代疗法领域占据市场主导地位，2023 年份额为 72.3%。
  • 2023年法布瑞氏症治疗市场中，北美将占最大份额，超过45.1%，其次是欧洲。
  • 预计亚太地区在预测期内成长最快，其次是拉丁美洲。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章法布瑞氏症治疗市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 法布瑞氏症治疗市场分析工具
    • 波特的分析
    • PESTEL分析

第四章法布瑞氏症治疗市场：依治疗方法估计与趋势分析

  • 细分仪表板
  • 法布瑞氏症治疗市场：治疗方法变异分析，百万美元，2023 年和 2030 年
  • 酵素替代疗法
  • Chaperone治疗
  • 基材减少疗法
  • 其他的

第五章法布瑞氏症治疗市场：依途径估计与趋势分析

  • 细分仪表板
  • 法布瑞氏症治疗市场：途径变异分析，百万美元，2023 年和 2030 年
  • 静脉注射
  • 口服给药

第六章法布瑞氏症治疗市场：通路、前景、估计与趋势分析

  • 细分仪表板
  • 法布瑞氏症治疗市场：通路变化分析，百万美元，2023 年和 2030 年
  • 医院药房
  • 零售药房
  • 网路药房

第七章法布瑞氏症治疗市场：区域估计与趋势分析

  • 2023 年和 2030 年法布瑞氏症治疗市场占有率（按地区），百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Sanofi SA
    • Shire Plc.
    • Amicus Therapeutics Inc.
    • ISU Abxis Co Ltd.
    • JCR Pharmaceuticals Co Ltd.
    • Protalix Biotherapeutics Inc.
    • Idorsia Pharmaceuticals Ltd.
    • Avrobio Inc.
简介目录
Product Code: GVR-2-68038-747-6

Fabry Disease Treatment Market Growth & Trends:

The global fabry disease treatment market size is estimated to reach a value of USD 4.93 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 9.9% from 2024 to 2030. Rising cohort of Fabry disease, increasing adoption of novel therapies such as chaperone treatment, and potential approval of pipeline drugs including substrate reduction therapies and enzyme replacement therapies are providing a fillip to the market.

Fabry disease is a rare inherited lysosomal storage disorder caused by genetic mutation that interferes with function of alpha galactosidase enzyme. Fabry disease generally has a late onset with mild symptoms, due to which several patients are often undiagnosed. Standard of care for management of the disease is enzyme replacement therapy (ERT). Sanofi's Fabrazyme and Shire's Replagal are the only approved ERTs in the EU; however in the U.S., only Fabrazyme has been approved.

Focus of current clinical trials is to improve the safety and efficacy profile of ERTs and introduction of novel oral therapies that can eliminate the need for intravenous infusions. Recently, Amicus Therapeutics' Galafold has been approved as the first oral chaperone therapy for the treatment of adults in the U.S., Canada, EU, Japan, Australia, Israel, and South Korea.

North America held the largest share in the Fabry disease treatment market in 2017, followed by Europe. The growth of the region can be attributed to higher adoption of novel therapies, favorable reimbursement policies, and better healthcare facilities. However, high cost of therapy with ERTs such as Fabrazyme is an impediment for the market in developing regions.

Fabry Disease Treatment Market Report Highlights:

  • Intravenous route dominated the market with a market share of 65.9 % in 2023 and is also expected to grow at the fastest CAGR over the forecast period from 2024 to 2030.
  • The enzyme replacement treatment segment dominated the market and accounted for a share of 72.3 % in 2023.
  • North America commanded the leading market share of more than 45.1% in the Fabry disease treatment market, followed by Europe, in 2023
  • APAC is likely to witness the fastest growth during the forecast period, followed by Latin America, due to increasing healthcare expenditure and rising patient population

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Fabry Disease Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Fabry Disease Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Fabry Disease Market: Treatment Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Fabry Disease Market: Treatment Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Enzyme Replacement Therapy
    • 4.3.1. Enzyme Replacement Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Chaperone Treatment
    • 4.4.1. Chaperone Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Substrate Reduction Therapy
    • 4.5.1. Substrate Reduction Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Other Diseases
    • 4.6.1. Other Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Fabry Disease Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Fabry Disease Market: Route of Administration Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Intravenous Route
    • 5.3.1. Intravenous Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Oral Route
    • 5.4.1. Oral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Fabry Disease Market: Distribution Channel Outlook Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Fabry Disease Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacy
    • 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Fabry Disease Market: Regional Estimates & Trend Analysis

  • 7.1. Fabry Disease Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. South Korea
      • 7.4.7.1. South Korea Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.8. Thailand
      • 7.4.8.1. Thailand Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Fabry Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Sanofi S.A.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Shire Plc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Amicus Therapeutics Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. ISU Abxis Co Ltd.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. JCR Pharmaceuticals Co Ltd.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Protalix Biotherapeutics Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Idorsia Pharmaceuticals Ltd.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Avrobio Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives